Federici, G. & Soddu, S. Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers. J. Exp. Clin. Cancer Res 39, 46 (2020).
Harrison, S. M. & Rehm, H. L. Is ‘likely pathogenic’ really 90% likely? Reclassification data in ClinVar. Genome Med 11, 72 (2019).
Weston, K. P. et al. Identification of disease-linked hyperactivating mutations in UBE3A through large-scale functional variant analysis. Nat. Commun. 12, 6809 (2021).
Rehm, H. L. et al. ClinGen–the Clinical Genome Resource. N. Engl. J. Med 372, 2235–2242 (2015).
Spielmann, M. & Kircher, M. Computational and experimental methods for classifying variants of unknown clinical significance. Cold Spring Harb. Mol. Case Stud 8, a006196 (2022).
Kremer, L. S. et al. Genetic diagnosis of Mendelian disorders via RNA sequencing. Nat. Commun. 8, 15824 (2017).
Marwaha, S., Knowles, J. W. & Ashley, E. A. A guide for the diagnosis of rare and undiagnosed disease: beyond the exome. Genome Med 14, 23 (2022).
Alaimo, J. T. et al. Integrated analysis of metabolomic profiling and exome data supplements sequence variant interpretation, classification, and diagnosis. Genet Med 22, 1560–1566 (2020).
Almontashiri, N. A. M. et al. Clinical Validation of Targeted and Untargeted Metabolomics Testing for Genetic Disorders: A 3 Year Comparative Study. Sci. Rep. 10, 9382 (2020).
Adams, D. R. & Eng, C. M. Next-Generation Sequencing to Diagnose Suspected Genetic Disorders. N. Engl. J. Med 380, 201 (2019).
Fung, J. L. F. et al. A three-year follow-up study evaluating clinical utility of exome sequencing and diagnostic potential of reanalysis. NPJ Genom. Med 5, 37 (2020).
Lionel, A. C. et al. Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test. Genet Med 20, 435–443 (2018).
Investigators, G. P. P. et al. 100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care - Preliminary Report. N. Engl. J. Med 385, 1868–1880 (2021).
Cummings, B. B. et al. Improving genetic diagnosis in Mendelian disease with transcriptome sequencing. Sci Transl Med 9, aal5209 (2017).
Gonorazky, H. D. et al. Expanding the Boundaries of RNA Sequencing as a Diagnostic Tool for Rare Mendelian Disease. Am. J. Hum. Genet 104, 466–483 (2019).
Fresard, L. et al. Identification of rare-disease genes using blood transcriptome sequencing and large control cohorts. Nat. Med 25, 911–919 (2019).
Lee, H. et al. Diagnostic utility of transcriptome sequencing for rare Mendelian diseases. Genet Med 22, 490–499 (2020).
Murdock, D. R. et al. Transcriptome-directed analysis for Mendelian disease diagnosis overcomes limitations of conventional genomic testing. J Clin Invest 131, I141500 (2021).
Maddirevula, S. et al. Analysis of transcript-deleterious variants in Mendelian disorders: implications for RNA-based diagnostics. Genome Biol. 21, 145 (2020).
Wai, H. A. et al. Blood RNA analysis can increase clinical diagnostic rate and resolve variants of uncertain significance. Genet Med 22, 1005–1014 (2020).
Yépez, V. A. et al. Clinical implementation of RNA sequencing for Mendelian disease diagnostics. Genome Med 14, 38 (2022).
Yépez, V. A. et al. Detection of aberrant gene expression events in RNA sequencing data. Nat. Protoc. 16, 1276–1296 (2021).
Zwemer, L. M. & Bianchi, D. W. The amniotic fluid transcriptome as a guide to understanding fetal disease. Cold Spring Harb. Perspect. Med. 5, a023101 (2015).
Liu, P. & Vossaert, L. Emerging technologies for prenatal diagnosis: The application of whole genome and RNA sequencing. Prenat. Diagn. 42, 686–696 (2022).
Consortium, G. T. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348, 648–660 (2015).
Park, H. J., Cho, H. Y. & Cha, D. H. The Amniotic Fluid Cell-Free Transcriptome Provides Novel Information about Fetal Development and Placental Cellular Dynamics. Int. J. Mol. Sci. 22, h52612 (2021).
Hui, L., Slonim, D. K., Wick, H. C., Johnson, K. L. & Bianchi, D. W. The amniotic fluid transcriptome: a source of novel information about human fetal development. Obstet. Gynecol. 119, 111–118 (2012).
Sorber, L. et al. Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol. Cancers (Basel) 11,40458 (2019).
Alfirevic, Z., Navaratnam, K. & Mujezinovic, F. Amniocentesis and chorionic villus sampling for prenatal diagnosis. Cochrane Database Syst. Rev. 9, CD003252 (2017).
Underwood, M. A., Gilbert, W. M. & Sherman, M. P. Amniotic fluid: not just fetal urine anymore. J. Perinatol. 25, 341–348 (2005).
Hu, M. S. et al. Embryonic skin development and repair. Organogenesis 14, 46–63 (2018).
Mahoney, M. G., Muller, E. J. & Koch, P. J. Desmosomes and desmosomal cadherin function in skin and heart diseases-advancements in basic and clinical research. Dermatol Res Pract 2010, 725647 (2010).
Nazzaro, V. [Normal development of human fetal skin]. G Ital. Dermatol Venereol. 124, 421–427 (1989).
Lord, J. et al. Prenatal exome sequencing analysis in fetal structural anomalies detected by ultrasonography (PAGE): a cohort study. Lancet 393, 747–757 (2019).
Wright, C. F. et al. Making new genetic diagnoses with old data: iterative reanalysis and reporting from genome-wide data in 1133 families with developmental disorders. Genet Med 20, 1216–1223 (2018).
Wright, C. F. et al. Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data. Lancet 385, 1305–1314 (2015).
Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, 1523 (2019).
Normand, E. A. et al. Clinical exome sequencing for fetuses with ultrasound abnormalities and a suspected Mendelian disorder. Genome Med 10, 74 (2018).
Petrovski, S. et al. Whole-exome sequencing in the evaluation of fetal structural anomalies: a prospective cohort study. Lancet 393, 758–767 (2019).
Chung, C. C. Y. et al. Rapid whole-exome sequencing facilitates precision medicine in paediatric rare disease patients and reduces healthcare costs. Lancet Reg. Health West Pac. 1, 100001 (2020).
Kingsmore, S. F. et al. A Randomized, Controlled Trial of the Analytic and Diagnostic Performance of Singleton and Trio, Rapid Genome and Exome Sequencing in Ill Infants. Am. J. Hum. Genet 105, 719–733 (2019).
Wells, C. et al. A case of mild CHARGE syndrome associated with a splice site mutation in CHD7. Eur. J. Med Genet 59, 195–197 (2016).
Smirnov, D., Schlieben, L. D., Peymani, F., Berutti, R. & Prokisch, H. Guidelines for clinical interpretation of variant pathogenicity using RNA phenotypes. Hum. Mutat. 43, 1056–1070 (2022).
Layman, W. S., Hurd, E. A. & Martin, D. M. Chromodomain proteins in development: lessons from CHARGE syndrome. Clin. Genet 78, 11–20 (2010).
Meisner, J. K. & Martin, D. M. Congenital heart defects in CHARGE: The molecular role of CHD7 and effects on cardiac phenotype and clinical outcomes. Am. J. Med Genet C. Semin Med Genet 184, 81–89 (2020).
Asad, Z. et al. Rescue of neural crest-derived phenotypes in a zebrafish CHARGE model by Sox10 downregulation. Hum. Mol. Genet 25, 3539–3554 (2016).
Lettieri, A. et al. Semaphorin Regulation by the Chromatin Remodeler CHD7: An Emerging Genetic Interaction Shaping Neural Cells and Neural Crest in Development and Cancer. Front Cell Dev. Biol. 9, 638674 (2021).
Feng, W. et al. The chromatin remodeler CHD7 regulates adult neurogenesis via activation of SoxC transcription factors. Cell Stem Cell 13, 62–72 (2013).
Bajpai, R. et al. CHD7 cooperates with PBAF to control multipotent neural crest formation. Nature 463, 958–962 (2010).
Yan, S. et al. CHD7 regulates cardiovascular development through ATP-dependent and -independent activities. Proc. Natl Acad. Sci. USA 117, 28847–28858 (2020).
An, H. et al. Functional mechanism and pathogenic potential of MYRF ICA domain mutations implicated in birth defects. Sci. Rep. 10, 814 (2020).
Li, Z., Park, Y. & Marcotte, E. M. A Bacteriophage tailspike domain promotes self-cleavage of a human membrane-bound transcription factor, the myelin regulatory factor MYRF. PLoS Biol. 11, e1001624 (2013).
Lee, K. S. et al. Mutational spectrum of type I collagen genes in Korean patients with osteogenesis imperfecta. Hum. Mutat. 27, 599 (2006).
Odibo, A. O. 68-97 (John Wiley & Sons, Inc, 2015).
Enzensberger, C. et al. Fetal loss rate and associated risk factors after amniocentesis, chorionic villus sampling and fetal blood sampling. Ultraschall Med 33, E75–E79 (2012).
Bournazos, A. M. et al. Standardized practices for RNA diagnostics using clinically accessible specimens reclassifies 75% of putative splicing variants. Genet Med 24, 130–145 (2022).
Brnich, S. E. et al. Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework. Genome Med 12, 3 (2019).
Pervolaraki, E., Dachtler, J., Anderson, R. A. & Holden, A. V. The developmental transcriptome of the human heart. Sci. Rep. 8, 15362 (2018).
Ware, S. M. et al. The genetic architecture of pediatric cardiomyopathy. Am. J. Hum. Genet 109, 282–298 (2022).
Loukogeorgakis, S. P. & De Coppi, P. Stem cells from amniotic fluid–Potential for regenerative medicine. Best. Pr. Res Clin. Obstet. Gynaecol. 31, 45–57 (2016).
留言 (0)